ClinicalTrials.gg
CompletedNCT00509639Updated Dec 13, 2012

Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

A Phase 3 interventional study of 10% Metronidazole Ointment in Crohn's Disease, sponsored by S.L.A. Pharma AG. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-13.

Sponsored by S.L.A. Pharma AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 217 studies in Crohn Disease with a site in United Kingdom — 47 open to participants now, 66 under way, 26 of them phase 3. Crohn Disease · United Kingdom.

Enrollment
120th of 171
74 · median 168
Started
2005
with 1 other
Phase 3
71 of 217
16 open now
Registered
19th of 217
by date

Among the 217 studies in Crohn Disease with a site in United Kingdom, this one is the 120th largest by enrollment of the 171 interventional ones that give a count, is one of 2 that started in 2005, is one of 71 in phase 3, and was the 19th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

47 of the 217 studies in Crohn Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Crohn Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to compare changes in Perianal Crohn's Disease following use of locally applied 10% metronidazole ointment and a placebo.

Read the detailed description

Anorectal Crohn's disease is one of the most problematic and debilitating conditions encountered in colorectal practise. The condition is usually chronic, debilitating, and frequently refractory to current medications. Failure to respond to medical therapy may ultimately result in proctocolectomy and ileostomy, even in the absence of more proximal colonic disease. Isolated anorectal Crohn's disease is reported in 3 to 5% of Crohn's patients. In Crohn's patients as a whole, anorectal involvement is reported in up to one third to one half of patients, in addition to either colonic or enteric Crohn's disease. In spite of the previously reported painless nature of anorectal Crohn's disease, it is the author's experience that the condition can be inordinately painful due to deeply eroding fissures, oedematous skin tags, and painful induration of the perianal region.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Crohn's disease (diagnosed by radiology, endoscopy and pathology), with anorectal involvement.
  • Have had perianal symptoms for longer than 3 months
  • Have a PCDAI of 5 or above at baseline
  • Subjects can be on concomitant medication. Acceptable regimes are:-
  • Aminosalicylates at a dosage that has been stable for more than 4 weeks before screening;
  • Oral \<40mg per day that has been stable for more than 3 weeks;
  • Methotrexate given for at least 3 months that has been stable for more than 4 weeks; Azathioprine or mercaptopurine given for at least 6 months at dosage that has been stable for more than 8 weeks;
  • Antibiotics at a dosage that has been stable for 4 weeks (subjects may be on oral metronidazole but on a dose not more than 750mg per day),
  • Cycolsporin for more than 3 months and on a stable dose for more than 4 weeks;
  • Patients who have been treated with Infliximab must have received their initial dose 3 months before starting study medication and their most recent dose at least 8 weeks before starting study medication and not receive an infusion whilst in the double-blind treatment phase of the study for 4 weeks. During the second 4 week open stage of the study patients can commence again a maintenance regime with Infliximab treatment if deemed necessary
  • Any patients not on concurrent medication must have been off medication for at least 4 weeks before screening.
  • If patients have Setons these must have been in place for at least 4 weeks prior to screening.
  • Subjects must be aged 18 years or over and of the legal age of consent.
  • If female, the subject must not be lactating and must be (a) post- menopausal, (b) surgically sterilised, or (c) have a negative pregnancy test result prior to entry into the study and will use double- barrier methods of (two separate methods of birthcontrol one of which may include oral contraception) for the duration of the study.
  • Must have provided written to participate.

Exclusion criteria

Exclusion Criteria:

  • They have had surgery to the anus or rectum in the past 4 weeks;
  • They have a perianal abscess requiring incision and drainage;
  • They have a stoma of less than 6 months duration;
  • Allergic to metronidazole;
  • Are taking any prohibited medication.
  • Deemed mentally incompetent.
  • Considered by their physician unlikely to be able to comply with the protocol.
  • Taken part in an experimental drug study in the preceding three months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Metronidazole 10% ointment

    Metronidazole 10% ointment

    Drug: 10% Metronidazole Ointment

  • Placebo comparator
    Placebo ointment

    Placebo ointment

    Drug: 10% Metronidazole Ointment

Interventions

  • Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of 10% metronidazole ointment, applied topically three times a day, in and around the anus, on the change in perianal Crohn's disease activity.

    Perianal Crohn's Disease Activity Index

    Time frame: Four weeks

Secondary outcomes

  1. To evaluate and compare the relief of perianal pain and discomfort associated with Crohn's disease, against placebo.

    Perianal Crohn's Disease Activity Index plus Visual Analogue Scale for perianal pain

    Time frame: 4 weeks

  2. To evaluate and compare Patient Global Impression of Improvement

    Patient Global Impression of Improvement (numerical scale)

    Time frame: 4 weeks

  3. To compare visual improvement (using photographic documentation assessed by a blinded independent observer)

    Photographic record

    Time frame: 4 weeks

  4. To compare Quality of Life assessments

    Short Form 12 Questionnaire

    Time frame: 4 weeks

  5. To evaluate and compare the number of analgesics required prior to treatment and to that required by the treatment and placebo group

    Usage of analgesics during the treatment period

    Time frame: 4 weeks

  6. To evaluate and compare fistula healing

    Visual assessment of fistula healing

    Time frame: 4 weeks

07

Study locations

11 sites
  • Washington University School of Medicine
    St Louis, Missouri M 63110, United States
  • Derby City General Hospital
    Derby, Derbyshire DE22 3NE, United Kingdom
  • Leicester General Hospital
    Leicester, Leicestershire LE5 4PW, United Kingdom
  • Monklands Hospital
    Airdrie, ML6 0JS, United Kingdom
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Bristol Royal Infirmary
    Bristol, BS1 3NU, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • University Hospital of Warwick and Coventry
    Coventry, CV2 2DX, United Kingdom
  • St Marks Hospital
    Harrow, HA1 3UJ, United Kingdom
  • St Thomas Hospital
    London, SE1 &EH, United Kingdom
  • Peterborough District Hospital
    Peterborough, PE3 6DA, United Kingdom
08

References and documents

Publications

  • Maeda Y, Ng SC, Durdey P, Burt C, Torkington J, Rao PK, Mayberry J, Moshkovska T, Stone CD, Carapeti E, Vaizey CJ; Topical Metronidazole in Perianal Crohn's Study Group. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg. 2010 Sep;97(9):1340-7. doi: 10.1002/bjs.7121. PubMed 20632322 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2007
First posted
Jul 31, 2007
Start
May 2005
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
Dec 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00509639
Lead sponsor
S.L.A. Pharma AG
Responsible party
Sponsor
First posted
Jul 31, 2007
Start date
May 2005
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Dec 13, 2012

Study contacts

Emin Carapeti, BSc,MBBS,MD,
principal investigator · St Thomas Hospital, London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion